Review



tce cohort  (Optum Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Optum Inc tce cohort
    Definition of the cohorts of interests, inclusion and exclusion criteria. From <t>the</t> <t>Optum®</t> COVID-19 data, subjects with active COVID-19 or who received <t>TCE</t> treatment (blinatumomab) were isolated. The first COVID-19 infection or TCE treatment was considered a triggering event. Subjects with missing information on gender or age were excluded. Subjects with pre-existing comorbidities that share traits with CRS at least 7 days before the triggering event were excluded. A significant number of COVID-19 patients had no reported data 30 days around the triggering event and were excluded. Patients diagnosed with Sepsis within 30 days after onset were also excluded. Three cohorts of interest were used for subsequent CRS case identification: ‘COVID-19 adult cohort’, ‘TCE adult cohort’ and ‘TCE pediatric cohort’.
    Tce Cohort, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tce+cohort/pmc12953395-194-18-22?v=Optum+Inc
    Average 86 stars, based on 1 article reviews
    tce cohort - by Bioz Stars, 2026-06
    86/100 stars

    Images

    1) Product Images from "Guideline-based strategies to identify severe cytokine release syndrome in COVID-19 and cancer immunotherapy using large-scale electronic health records"

    Article Title: Guideline-based strategies to identify severe cytokine release syndrome in COVID-19 and cancer immunotherapy using large-scale electronic health records

    Journal: Frontiers in Digital Health

    doi: 10.3389/fdgth.2025.1625889

    Definition of the cohorts of interests, inclusion and exclusion criteria. From the Optum® COVID-19 data, subjects with active COVID-19 or who received TCE treatment (blinatumomab) were isolated. The first COVID-19 infection or TCE treatment was considered a triggering event. Subjects with missing information on gender or age were excluded. Subjects with pre-existing comorbidities that share traits with CRS at least 7 days before the triggering event were excluded. A significant number of COVID-19 patients had no reported data 30 days around the triggering event and were excluded. Patients diagnosed with Sepsis within 30 days after onset were also excluded. Three cohorts of interest were used for subsequent CRS case identification: ‘COVID-19 adult cohort’, ‘TCE adult cohort’ and ‘TCE pediatric cohort’.
    Figure Legend Snippet: Definition of the cohorts of interests, inclusion and exclusion criteria. From the Optum® COVID-19 data, subjects with active COVID-19 or who received TCE treatment (blinatumomab) were isolated. The first COVID-19 infection or TCE treatment was considered a triggering event. Subjects with missing information on gender or age were excluded. Subjects with pre-existing comorbidities that share traits with CRS at least 7 days before the triggering event were excluded. A significant number of COVID-19 patients had no reported data 30 days around the triggering event and were excluded. Patients diagnosed with Sepsis within 30 days after onset were also excluded. Three cohorts of interest were used for subsequent CRS case identification: ‘COVID-19 adult cohort’, ‘TCE adult cohort’ and ‘TCE pediatric cohort’.

    Techniques Used: Isolation, Infection



    Similar Products

    tce cohort  (Optum Inc)
    86
    Optum Inc tce cohort
    Definition of the cohorts of interests, inclusion and exclusion criteria. From <t>the</t> <t>Optum®</t> COVID-19 data, subjects with active COVID-19 or who received <t>TCE</t> treatment (blinatumomab) were isolated. The first COVID-19 infection or TCE treatment was considered a triggering event. Subjects with missing information on gender or age were excluded. Subjects with pre-existing comorbidities that share traits with CRS at least 7 days before the triggering event were excluded. A significant number of COVID-19 patients had no reported data 30 days around the triggering event and were excluded. Patients diagnosed with Sepsis within 30 days after onset were also excluded. Three cohorts of interest were used for subsequent CRS case identification: ‘COVID-19 adult cohort’, ‘TCE adult cohort’ and ‘TCE pediatric cohort’.
    Tce Cohort, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tce+cohort/pmc12953395-194-18-22?v=Optum+Inc
    Average 86 stars, based on 1 article reviews
    tce cohort - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Definition of the cohorts of interests, inclusion and exclusion criteria. From the Optum® COVID-19 data, subjects with active COVID-19 or who received TCE treatment (blinatumomab) were isolated. The first COVID-19 infection or TCE treatment was considered a triggering event. Subjects with missing information on gender or age were excluded. Subjects with pre-existing comorbidities that share traits with CRS at least 7 days before the triggering event were excluded. A significant number of COVID-19 patients had no reported data 30 days around the triggering event and were excluded. Patients diagnosed with Sepsis within 30 days after onset were also excluded. Three cohorts of interest were used for subsequent CRS case identification: ‘COVID-19 adult cohort’, ‘TCE adult cohort’ and ‘TCE pediatric cohort’.

    Journal: Frontiers in Digital Health

    Article Title: Guideline-based strategies to identify severe cytokine release syndrome in COVID-19 and cancer immunotherapy using large-scale electronic health records

    doi: 10.3389/fdgth.2025.1625889

    Figure Lengend Snippet: Definition of the cohorts of interests, inclusion and exclusion criteria. From the Optum® COVID-19 data, subjects with active COVID-19 or who received TCE treatment (blinatumomab) were isolated. The first COVID-19 infection or TCE treatment was considered a triggering event. Subjects with missing information on gender or age were excluded. Subjects with pre-existing comorbidities that share traits with CRS at least 7 days before the triggering event were excluded. A significant number of COVID-19 patients had no reported data 30 days around the triggering event and were excluded. Patients diagnosed with Sepsis within 30 days after onset were also excluded. Three cohorts of interest were used for subsequent CRS case identification: ‘COVID-19 adult cohort’, ‘TCE adult cohort’ and ‘TCE pediatric cohort’.

    Article Snippet: First, we do not know the origin of the TCE patients and we cannot exclude that this specific TCE cohort within the Optum COVID-19 data may derive from a study focusing on patients with specific comorbidities.

    Techniques: Isolation, Infection